DK0460076T3 - Genetisk manipulerede immunoglobuliner - Google Patents

Genetisk manipulerede immunoglobuliner

Info

Publication number
DK0460076T3
DK0460076T3 DK90904172.5T DK90904172T DK0460076T3 DK 0460076 T3 DK0460076 T3 DK 0460076T3 DK 90904172 T DK90904172 T DK 90904172T DK 0460076 T3 DK0460076 T3 DK 0460076T3
Authority
DK
Denmark
Prior art keywords
genetically engineered
engineered immunoglobulins
immunoglobulins
preparing
found
Prior art date
Application number
DK90904172.5T
Other languages
Danish (da)
English (en)
Inventor
Maurizio Zanetti
Maurizio Sollazzo
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23227670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0460076(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK0460076T3 publication Critical patent/DK0460076T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK90904172.5T 1989-02-24 1990-02-23 Genetisk manipulerede immunoglobuliner DK0460076T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31614489A 1989-02-24 1989-02-24

Publications (1)

Publication Number Publication Date
DK0460076T3 true DK0460076T3 (da) 1996-03-25

Family

ID=23227670

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90904172.5T DK0460076T3 (da) 1989-02-24 1990-02-23 Genetisk manipulerede immunoglobuliner

Country Status (9)

Country Link
US (3) US5508386A (ja)
EP (1) EP0460076B1 (ja)
JP (2) JP3355351B2 (ja)
AT (1) ATE130765T1 (ja)
CA (1) CA2047244C (ja)
DE (2) DE69023900T4 (ja)
DK (1) DK0460076T3 (ja)
ES (1) ES2082850T3 (ja)
WO (1) WO1990009804A1 (ja)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009804A1 (en) * 1989-02-24 1990-09-07 The Regents Of The University Of California Genetically engineered immunoglobulins
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5817308A (en) 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
WO1997042973A1 (en) * 1996-05-15 1997-11-20 Altarex, Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
US7361346B1 (en) * 1996-05-15 2008-04-22 Altarex Corp. Therapeutic compositions that produce an immune response
US6737057B1 (en) * 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US20020081298A1 (en) * 1997-01-07 2002-06-27 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
EP1030684A4 (en) * 1997-11-14 2004-09-15 Euro Celtique Sa MODIFIED ANTIBODIES WITH IMPROVED CAPACITY TO TRIGGER ANTI-IDIOTYPE RESPONSE
JP2002508933A (ja) * 1997-12-24 2002-03-26 ダイアテック・ピーティワイ・リミテッド 二官能分子
US7279462B1 (en) 1998-04-27 2007-10-09 Nevagen Llc Somatic transgene immunization and related methods
JP2003535021A (ja) * 1998-11-13 2003-11-25 ユーロ−セルティーク，エス．エイ． 抗体ワクチン避妊薬
KR20020000218A (ko) * 1999-02-25 2002-01-05 추후제출 네이키드 플라스미드 디엔에이를 이용한 집 먼지 진드기알레르겐용 백신
JP5000807B2 (ja) * 1999-04-27 2012-08-15 ネバジェン エルエルシー 体細胞導入遺伝子免疫および関連方法
AU1084901A (en) 1999-10-14 2001-04-23 Martha S. Hayden-Ledbetter Dna vaccines encoding antigen linked to a domain that binds cd40
AU2001241533A1 (en) * 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
IL151927A0 (en) 2000-03-31 2003-04-10 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US6801270B2 (en) * 2000-06-26 2004-10-05 Reveo, Inc. Backlight for a liquid crystal display having high light-recycling efficiency
GB0102145D0 (en) * 2001-01-26 2001-03-14 Scancell Ltd Substances
WO2002078612A2 (en) * 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production
WO2003015716A2 (en) 2001-08-13 2003-02-27 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof
ES2338305T3 (es) * 2001-09-28 2010-05-06 Purdue Research Foundation Metodo de tratamiento que utiliza conjugados ligando-inmunogeno.
AU2003218181A1 (en) * 2002-03-15 2003-09-29 Multicell Immunotherapeutics, Inc. Immunostimulatory double stranded RNA and methods of inducing, enhancing or modulating the immune response
EP2258712A3 (en) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
US20070037769A1 (en) * 2003-03-14 2007-02-15 Multicell Immunotherapeutics, Inc. Compositions and methods to treat and control tumors by loading antigen presenting cells
US7744876B2 (en) 2002-04-09 2010-06-29 The Curators Of The University Of Missouri Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes
US8603472B2 (en) 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
CA2481437A1 (en) 2002-04-09 2003-10-16 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
US8609091B2 (en) 2002-04-09 2013-12-17 The Curators Of The University Of Missouri Method for endocytic presentation of an immunosuppressive for the treatment of type 1 diabetes
US8603471B2 (en) 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions for preventing the onset of type 1 diabetes
JP2005522483A (ja) * 2002-04-11 2005-07-28 アルタレックス メディカル コーポレーション 結合剤及び腫瘍細胞をターゲティングする際のそれらの使用
CA2482924A1 (en) * 2002-04-19 2003-10-30 Endocyte, Inc. Adjuvant enhanced immunotherapy
JP2006522806A (ja) * 2003-03-26 2006-10-05 マルチセル・イミュノセラピューティクス，インコーポレイテッド 細胞死及び／又はアポトーシスを誘導するための、選択されたｒｎａモチーフ
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
CN101166976B (zh) * 2005-01-13 2013-06-12 诺华疫苗和诊断公司 利用朊病毒特异性肽试剂的elisa试验
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
US20070111237A1 (en) * 2005-09-14 2007-05-17 Maurizio Zanetti Process for identifying antigenized antibodies using ribosome cell free expression system
US8168164B2 (en) * 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
EP1887084A1 (en) 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
US8865179B2 (en) * 2008-01-26 2014-10-21 Swey-Shen Alexchen Aptameric IgE peptides in a protein scaffold as an allergy vaccine
WO2009134942A1 (en) * 2008-04-30 2009-11-05 Novartis Ag. Assay for pathogenic conformers
CN107427590B (zh) 2015-02-02 2021-08-31 伯明翰大学 具有多个t细胞表位的靶向部分肽表位复合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003950A1 (fr) * 1982-11-30 1988-06-02 Marc Girard PEPTIDES COMPORTANT UN SITE IMMUNOGENE DU POLIOVIRUS ET ADNs CONTENANT DES SEQUENCES NUCLEOTIDIQUES CODANT POUR CES PEPTIDES
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4631191A (en) * 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
WO1990009804A1 (en) * 1989-02-24 1990-09-07 The Regents Of The University Of California Genetically engineered immunoglobulins
EP0580758A4 (en) * 1991-04-18 1995-04-05 Sinai School Medicine RECOMBINANT ANTI-HIV ANTIBODIES.

Also Published As

Publication number Publication date
JP2001190295A (ja) 2001-07-17
DE69023900T4 (de) 1996-10-02
JP3355351B2 (ja) 2002-12-09
US5583202A (en) 1996-12-10
US5658762A (en) 1997-08-19
EP0460076A4 (en) 1992-08-05
JP3357890B2 (ja) 2002-12-16
JPH04503605A (ja) 1992-07-02
US5508386A (en) 1996-04-16
CA2047244C (en) 2002-09-17
ES2082850T3 (es) 1996-04-01
WO1990009804A1 (en) 1990-09-07
DE69023900D1 (de) 1996-01-11
EP0460076B1 (en) 1995-11-29
EP0460076A1 (en) 1991-12-11
CA2047244A1 (en) 1990-08-25
DE69023900T2 (de) 1996-07-04
ATE130765T1 (de) 1995-12-15

Similar Documents

Publication Publication Date Title
DK0460076T3 (da) Genetisk manipulerede immunoglobuliner
DE3484664D1 (de) Rekombinante immunoglobulin-praeparate, verfahren zu ihrer herstellung, dna-sequenzen, expressionsvektoren und rekombinante wirkzellen hierfuer.
EP0699755A3 (en) Process for obtaining modified immunoglobulins with reduced immunogenicity of the variable domains of a murine antibody, compositions containing them
SE9201331D0 (sv) Protein l och hybridproteiner daerav
DE69535719D1 (de) Fas-antigenbindender ligand
ATE196162T1 (de) Toxoplasma gondii-antigene, ihre herstellung und ihre verwendung
MX24652A (es) Compuestos de adn recombinante, vectores para la expresion de formas zimogenas de proteina c humana, celulas huesped transformadas y metodo para la prduccion recombinante de formas zimogenas de la proteina c humana.
NZ296564A (en) Method of improving antigenicity of antigens or haptens, fusion with rsv peptides; vaccines, vectors, nucleotides
DE69029808T2 (de) Monoklonale antikörper
ATE315658T1 (de) Genkonstrukte für genimmunisierung
SG95574A1 (en) Immunoreactive antigens of hepatitia e virus
DE68907735T2 (de) Genfragmente, die die variable Region eines Anti-HIV-Antikörpers codieren, von diesen exprimierte chimäre Anti-HIV-Antikörper und Verfahren zu deren Herstellung.
ATE233811T1 (de) Blutplaettchen-gpiiia p1a1 und -p1a2-epitope, ihre herstellung und verwendung
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.
DK0476059T3 (da) Fremgangsmåder til forøgelse af modificeringshastigheden for metastabile bindinger
DE69931282D1 (de) Nukleinsäure die in menschliche Tumoren vervielfältigt sind, und damit zusammenhängende Materiale und Verfahren
MX24651A (es) Compuestos de adn recombinante, vectores de expresion de mutantes de glicosilacion de la proteina c humana, celulas huesped transformadas y metodo para la produccion recombinante de formas zimogenas de proteina c humana.
DE69923092D1 (de) Nukleinsäure die in menschliche Tumoren vervielfältigt sind, und damit zusammenhängende Materiale und Verfahren
DE69927190D1 (de) Nukleinsäure die in menschliche Tumoren vervielfältigt sind, und damit zusammenhängende Materiale und Verfahren
ATE92102T1 (de) Genfragmente, die die variable region eines anti- hiv-antikoerpers codieren, von diesen exprimierte chimaere anti-hiv-antikoerper und verfahren zu deren herstellung.